Baricitinib 4mg and 2mg once-daily reduced pain in both patients who were opioid users and non-users in active rheumatoid arthritis: a post-hoc analysis of phase 3 trials

Lignende værker

• Pain reduction in rheumatoid arthritis patients who use opioids: a post hoc analysis of phase 3 trials of baricitinib
  af: Pope, JE, et al.
  Udgivet: (2021)
• Efficacy, safety and tolerability of duloxetine 60 mg once daily in major depression.
  af: Cowen, P, et al.
  Udgivet: (2005)
• Assessment of pain improvement in rheumatoid arthritis patients treated with baricitinib, who were inadequate responders to methotrexate and tumor necrosis factor inhibitors
  af: Taylor, P, et al.
  Udgivet: (2019)
• Improved patient-reported outcomes in patients with rheumatoid arthritis who failed adalimumab or placebo treatment and were rescued with baricitinib
  af: Fautrel, B, et al.
  Udgivet: (2017)
• Patient disease trajectories in rheumatoid arthritis patients treated with baricitinib 4-mg in 4 phase 3 clinical studies
  af: Taylor, PC, et al.
  Udgivet: (2023)